argenx (NASDAQ:ARGX – Free Report) had its target price boosted by Citigroup from $512.00 to $635.00 in a research note published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.
A number of other research firms have also recently commented on ARGX. HC Wainwright raised their price target on argenx from $504.00 to $533.00 and gave the company a “buy” rating in a report on Friday, July 26th. Barclays raised argenx from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, August 6th. Raymond James restated a “strong-buy” rating and issued a $605.00 price target on shares of argenx in a research note on Thursday, October 10th. JPMorgan Chase & Co. lifted their price objective on shares of argenx from $500.00 to $640.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $550.44.
View Our Latest Analysis on argenx
argenx Trading Up 0.6 %
argenx (NASDAQ:ARGX – Get Free Report) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The firm had revenue of $489.43 million during the quarter, compared to analysts’ expectations of $436.66 million. During the same period in the prior year, the company posted ($1.69) earnings per share. On average, analysts predict that argenx will post -0.37 EPS for the current year.
Institutional Investors Weigh In On argenx
Several institutional investors have recently modified their holdings of ARGX. Blue Trust Inc. raised its holdings in argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after buying an additional 62 shares during the period. J.Safra Asset Management Corp increased its position in argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of argenx by 420.0% in the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after acquiring an additional 63 shares during the period. Mather Group LLC. bought a new stake in shares of argenx in the 1st quarter worth about $38,000. Finally, Point72 Hong Kong Ltd purchased a new position in shares of argenx during the 2nd quarter worth about $76,000. 60.32% of the stock is owned by institutional investors.
argenx Company Profile
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Read More
- Five stocks we like better than argenx
- Why is the Ex-Dividend Date Significant to Investors?
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- What is the Nikkei 225 index?
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- How to Invest in Insurance Companies: A Guide
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.